A Comparative Study on the Impact of HucMSCs, Exosomes, and Conditioned Medium on Non-Alcoholic Steatohepatitis (NASH) – Findings from Scientific...
The Alfasigma Acquisition: A Response to the Failure of NASH Candidate Interception In the world of pharmaceuticals, the pursuit of...
Canaccord Downgrades Intercept to Hold and Provides Analysis on Alfasigma Deal In a recent development, Canaccord Genuity, a leading global...
Patients with alcohol abuse are more likely to visit emergency departments Alcohol abuse is a significant public health issue that...
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company, has recently announced the initiation of a Phase 2a clinical trial to evaluate the...
Sequana Medical, a pioneering medical device company, recently released its H1 2023 results and provided a comprehensive business update in...
Nimbus Therapeutics, a leading biotechnology company, has recently announced its successful completion of a significant fundraising round, securing an impressive...
Decompensated cirrhosis caused by non-alcoholic steatohepatitis (NASH) is a severe liver condition that occurs as a result of long-term inflammation...
An Overview of the Key Players in Decompensated Cirrhosis Caused by Nonalcoholic Steatohepatitis (NASH) Nonalcoholic steatohepatitis (NASH) is a progressive...
AusperBio, a leading biotechnology company, has recently announced that it has received FDA clearance for its Investigational New Drug (IND)...
Liver dysfunction is a serious medical condition that affects millions of people worldwide. It can be caused by a variety...
Marijuana, also known as cannabis, has been a topic of debate for many years. While some people believe that it...
